Cocrystal Pharma, INC 10-Q quarterly reports

Cocrystal Pharma, Inc. reported its second quarter 2026 financial results, highlighting ongoing research and development efforts but also substantial net losses and a critical need for future financing.

Cocrystal Pharma reported a net loss of $2.3 million for Q1 2026, with cash reserves projected to last less than 12 months, while advancing its antiviral drug candidates.

Cocrystal Pharma reported reduced net losses and R&D expenses while advancing its influenza and norovirus/coronavirus programs, but faces substantial doubt about its ability to continue as a going concern.

Cocrystal Pharma reported significant net losses and declining cash, raising substantial doubt about its ability to continue as a going concern, despite progress in antiviral drug development.

Cocrystal Pharma's Q1 2025 results show a reduced net loss compared to the previous year, driven by decreased research and development expenses, but the company expresses concerns about its ability to continue as a going concern without additional funding.

Cocrystal Pharma reported a net loss of $4.939 million for the third quarter of 2024, while continuing to advance its antiviral drug development programs.

Cocrystal Pharma reported a net loss of $9.3 million for the first half of 2024, while advancing its antiviral drug candidates through clinical trials.

Cocrystal Pharma reported a net loss of $3.956 million for the first quarter of 2024, while advancing its clinical programs for influenza, coronavirus, and norovirus.